论文部分内容阅读
Avastin与血管内皮生长因子(VEGF)结合并阻断其生物活性,从而抑制新生血管的生成,目前已逐渐应用于各种眼部新生血管性及渗出性疾病的治疗,并取得了显著疗效。基于VEGF及其受体在体内正常组织广泛表达,并在血管发育、神经保护及其他正常生理活动中起重要作用,干扰这一途径,如特异性或过度抗VEGF治疗将导致正常生理功能的缺失,继而诱导产生不良反应。因而,通过体内外基础实验及临床应用研究其用药安全性至关重要,目前已受到眼科医师及学者的广泛关注。
Avastin and vascular endothelial growth factor (VEGF) binding and blocking its biological activity, thereby inhibiting angiogenesis, has been gradually applied to a variety of ocular neovascularization and exudative disease treatment, and achieved significant results. VEGF and its receptors are widely expressed in normal tissues in vivo and play an important role in vascular development, neuroprotection, and other normal physiological activities that interfere with this pathway as specific or over-anti-VEGF treatment will result in the loss of normal physiological functions , And then induce adverse reactions. Therefore, it is very important to study the drug safety through basic experiments and clinical applications in vivo and in vitro. At present, it has been widely concerned by ophthalmologists and scholars.